MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Prostate
Vir Biotechnology, Inc. (NASDAQ:VIR)
Organization & Developments: Vir Biotechnology
Parents
Vir Biotechnology, Inc. (NASDAQ:VIR)
Children
*The company has 4 key platforms, including antibodies, siRNA, T-Cell and innate immunity.
2020: Covid Report: Moderna And Other Vaccine Makers Catapult On Key Test
2020: Vir Biotechnology Identifies Two Antibodies That Bind to the Spike Protein of 2019-nCoV, Newly Named as SARS-CoV-2
2020: Vir Biotechnology: Small-Cap Player That Lets Others Do The Heavy Lifting
2021: Vir Biotechnology: Not Nearly Enough
2021: Vir Biotechnology: Riding The COVID-19 Wave
2021: Vir Biotechnology: Still Valued On Potential, Which May Not Pan Out
2021: Vir stock soars on blinded, 8-subject hepatitis B analysis
2022: Vir Biotechnology (VIR) Presents at AASLD The Liver Meeting 2022_ seekingalpha.com
2022: Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
2022: Vir Biotechnology: Collaborative Approach To Taking On Serious Diseases_ seekingalpha.com
2022: Vir Biotechnology: Expanded Hepatitis Pipeline And COVID-19 Revenue Expected_seekingalpha.com
2023: Vir Biotechnology: A Relentless Slide In The Stock, Unresponsive To Positive Developments
2024: Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis
2024: Sticking With Vir Biotechnology_seekingalpha.com
2024: Vir Bio trims staff and pipeline to focus on Sanofi-licensed programmes
2024: Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January_ seekingalpha.com
2024: Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
2024: Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off
2024: Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off_ seekingalpha.com
2024: VIR Biotechnology's SWOT analysis: stock poised for growth amid challenges
2024: Vir gains T-cell engagers from Sanofi, loses 25% of staff in another pipeline switch-up_fiercebiotech
2025: Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong?
2025: Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology_ seekingalpha.com
2025: Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment
2026: Researchers praise ‘stunning’ results of new prostate cancer treatment
2026: Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Jumps
*Key People: Vir Biotechnology
Finance & Acquisitions: Vir Biotechnology